Q-omics provides the consensus-scored SMG1P6 profile across patient tissues and cancer cell-line models. SMG1P6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMG1P6 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SMG1P6 RNA expression shows 18,540 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where SMG1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMG1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMG1P6 survival associations across molecular data types. SMG1P6 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMG1P6 RNA expression–survival associations across cancer types. High SMG1P6 expression shows unfavorable associations in ACC, COAD and LGG, but favorable associations in HNSC, BLCA and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMG1P6 RNA expression.
This table summarizes SMG1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SMG1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMG1P6 shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, LUSC, KICH and COAD. The HNSC box plot shows higher SMG1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.077, t-test p < 0.001).
This table shows molecular features associated with SMG1P6 in patient tissues and cancer cell lines. In patient samples, SMG1P6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
